First Manhattan
ABMD

First Manhattan’s Abiomed Inc ABMD Stock Holding History

First Manhattan’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-26,117
Closed -$7.6M – 1439
2018
Q1 		$7.6M Buy
26,117
+17,571
+206% +$4.45M 0.04% 214
2017
Q4 		$1.6M Buy
8,546
+552
+7% +$103K 0.01% 387
2017
Q3 		$1.35M Buy
+7,994
New +$1.21M 0.01% 393

Other funds holding ABMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

First Manhattan's ABMD Position: Q2 2018 in Review

First Manhattan sold out of Abiomed Inc (ABMD) in Q2 2018, closing a stake of 26,117 shares — an estimated $7.6M sold.

First Manhattan first reported a position in ABMD in Q3 2017 and held it in 3 quarters. The position peaked at $7.6M in Q1 2018. 527 funds tracked by Wall St. Rank hold ABMD as of Q2 2018.

  • First Manhattan reported no remaining Abiomed Inc position as of Q2 2018 after selling out during the quarter.
  • First Manhattan sold 26,117 Abiomed Inc shares in Q2 2018, an estimated $7.6M.
  • First Manhattan first reported a position in Abiomed Inc in Q3 2017 and held it in 3 quarters.
  • First Manhattan's Abiomed Inc position peaked at $7.6M in Q1 2018.
  • 527 funds tracked by Wall St. Rank held Abiomed Inc as of Q2 2018.

Based on First Manhattan's 13F filing for Q2 2018, filed 1 Aug 2018.